184 related articles for article (PubMed ID: 24887664)
1. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma.
Shetty SJ; Bathla L; Govindarajan V; Thomas P; Loggie BW
Am Surg; 2014 Apr; 80(4):348-52. PubMed ID: 24887664
[TBL] [Abstract][Full Text] [Related]
2. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
3. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
[TBL] [Abstract][Full Text] [Related]
4. Malignant Peritoneal Mesothelioma: Treatment Options and Survival.
Salo SAS; Ilonen I; Laaksonen S; Myllärniemi M; Salo JA; Rantanen T
Anticancer Res; 2019 Feb; 39(2):839-845. PubMed ID: 30711965
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
Iversen LH; Rasmussen PC; Hagemann-Madsen R; Laurberg S
Colorectal Dis; 2013 Jul; 15(7):e365-72. PubMed ID: 23458368
[TBL] [Abstract][Full Text] [Related]
6. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience.
Chua TC; Yan TD; Morris DL
J Surg Oncol; 2009 Feb; 99(2):109-13. PubMed ID: 19016259
[TBL] [Abstract][Full Text] [Related]
9. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
[TBL] [Abstract][Full Text] [Related]
10. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
[TBL] [Abstract][Full Text] [Related]
11. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
Yan TD; Deraco M; Baratti D; Kusamura S; Elias D; Glehen O; Gilly FN; Levine EA; Shen P; Mohamed F; Moran BJ; Morris DL; Chua TC; Piso P; Sugarbaker PH
J Clin Oncol; 2009 Dec; 27(36):6237-42. PubMed ID: 19917862
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Zahid A; Clarke L; Carr N; Chandrakumaran K; Tzivanakis A; Dayal S; Mohamed F; Cecil T; Moran BJ
BJS Open; 2021 Mar; 5(2):. PubMed ID: 33688945
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
Sun JH; Ji ZH; Peng KW; Wu HT; Zhang Q; Yonemura Y; Li Y
Int J Hyperthermia; 2016 May; 32(3):289-97. PubMed ID: 26982735
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.
Hubert J; Thiboutot E; Dubé P; Cloutier AS; Drolet P; Sideris L
Surg Oncol; 2015 Mar; 24(1):41-6. PubMed ID: 25680983
[TBL] [Abstract][Full Text] [Related]
16. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
[TBL] [Abstract][Full Text] [Related]
17. [Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis].
Habbel VSA; Mahler EA; Feyerabend B; Oldhafer KJ; Lipp MJ
Z Gastroenterol; 2020 Feb; 58(2):146-151. PubMed ID: 32050285
[TBL] [Abstract][Full Text] [Related]
18. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
Su YD; Yang ZR; Li XB; Yu Y; Du XM; Li Y
Int J Hyperthermia; 2022; 39(1):706-712. PubMed ID: 35485308
[TBL] [Abstract][Full Text] [Related]
19. [Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy].
Passot G; Cotte E; Brigand C; Beaujard AC; Isaac S; Gilly FN; Glehen O
J Chir (Paris); 2008; 145(5):447-53. PubMed ID: 19106865
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma.
Klos D; Hanuliak J; Lemstrova R; Mohelnikova-Duchonova B; Zapletalova J; Melichar B; Risko J
Bratisl Lek Listy; 2023; 124(5):345-350. PubMed ID: 36876363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]